Medical Research Future Fund (MRFF)

Monash Partners Roadshow Feb 7 to Feb 21 2019

MHTP:: Peninsula :: Alfred Research Alliance :: Epworth:: Eastern Health :: Cabrini
Translational Research: the pipeline into the abyss
Unidirectional translational research

Figure 3: Health and medical research pathway from bench-to-bedside to practice

Implementation and translation
Silo’s and lack of systems approaches
Systems level barriers

**System design and metrics**
Dysfunctional system

1 - **Hospitals**
   Episodes of care, waiting times, patient flow, quality metrics

2 - **University**
   Student enrolments, higher degree completions

3 - **Research Entities**
   Bibliometrics, grants, investor-led paradigm

4 - **Primary Care**
   Private businesses
Improvement and Innovation through Collaboration

Better Health Through Research
Our Vision

Community
Healthcare Professionals
Hospitals, services, and primary care

Researchers
MRIs and universities

Investors
Governments, business, and philanthropy

High quality health system and outcomes
Model

- **Health**
  - Health system priorities & engagement, accessible data driven quality improvement & efficiencies
  - Public Hospitals
  - Private Hospitals
  - Primary & Ambulatory Care
  - Community & Public Health

- **Research**
  - Interactive & iterative research, innovation, evaluation & scale-up

- **Education**
  - Capacity building within the system
Translation Research Centres

Types of Participation in Communities of Practice

- outsiders
- tangential
- peripheral
- episodic
- experts
- regular
- beginners
- leaders
- core

adapted from Wenger, 2002
AUSTRALIAN MEDICAL RESEARCH AND INNOVATION STRATEGY 2016-2021

AUSTRALIAN MEDICAL RESEARCH AND INNOVATION PRIORITIES 2016-2018

Medical Research Future Fund

- Data and Infrastructure
- Trials and Translation
- Commercialisation

- Health Services and Systems
- Capacity and Collaboration
- Strategic and International horizons
AUSTRALIAN MEDICAL RESEARCH AND INNOVATION STRATEGY 2016-2021
Monash Partners Academic Health Science Centre
### Clinical Themes
- Cancer and Blood Diseases
- Cardiovascular Diseases
- Critical Care, Trauma and Perioperative Medicine
- Infection and Inflammation
- Metabolic Medicine
- Neuroscience, Mental Health and Sleep
- Women’s and Children’s Health

### Enabling Platforms
- Biomedical Discovery Research Integration
- Clinical Research Facilitation
- Community and Consumer Involvement *
- Data-Driven Healthcare and Informatics *
- Health Services Research, Implementation and Innovation *
- Primary and Community Health *
- Workforce Development

* MRFF funded
Monash Partners - Plan at a glance

**OUR STRATEGIC PRIORITIES AND GOALS**

**DATA-DRIVEN HEALTHCARE IMPROVEMENT**
- Integrating across the care continuum
- Integrating across translational research continuum

**CLINICAL INNOVATION THROUGH RESEARCH TO PRACTICE AND IMPACT**
- Building a research, translation and impact culture
- Building a workforce to deliver better health through research

**LEADING THEME FLAGSHIPS TO DIRECTLY BENEFIT OUR COMMUNITY**
- Measurement for success
- Clinical research facilitation

*Our purpose is to connect researchers, clinicians and the community to innovate for better health.*
Funding MRFF- $8M to date
Community are the funders and the beneficiaries of healthcare
Community are largely the funders and beneficiaries of health and medical research
Improving health care is NOT primarily a competitive space: Strategic, collaborative research and translation is fundamental
Australian Health Research Alliance

AHRTC & CIRH projects

National System wide initiatives

Indigenous health
Data for clinical improvement
Health services research
Consumer & Community Involvement
Clinical Research Facilitation
$85M invested to date from MRFF
Substantive State Government funding
Philanthropy and partner funding
Thank you

www.monashpartners.org.au
Medical Research Future Fund (MRFF)
### MRFF BUDGET

**OPEN AND TARGETED (47%)**  
Used primarily for Missions with specific ambitious goals

**TARGETED (9%)**  
Includes Accelerated Research and direct funding to AHRTCs and CIRHS

**OPEN (44%)**  
Includes clinical trials, fellowships, Frontiers, BioMedTech Horizons

**MISSIONS (36%)**  
- Strategic and international horizons
- Data and infrastructure
- Health services and systems
- Capacity and collaboration
- Trials and translation
- Commercialisation

**TRANSLATION (25%)**  
- Health services and systems
- Capacity and collaboration
- Trials and translation

**PATIENTS (19%)**  
- Health services and systems
- Trials and translation

**RESEARCHERS (20%)**  
- Strategic and international horizons
- Capacity and collaboration

<table>
<thead>
<tr>
<th>MRFF</th>
<th>2016-17 $m</th>
<th>2017-18 $m</th>
<th>2018-19 $m</th>
<th>2019-20 $m</th>
<th>2020-21 $m</th>
<th>2021-22 $m</th>
<th>OUTYEARS $m</th>
<th>TOTAL $m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Committed</td>
<td>18.0</td>
<td>143.4</td>
<td>222.4</td>
<td>317.4</td>
<td>357.0</td>
<td>222.0</td>
<td>437.5</td>
<td>1,717.6</td>
</tr>
<tr>
<td>Available</td>
<td>18.0</td>
<td>143.4</td>
<td>222.4</td>
<td>392.7</td>
<td>650.2</td>
<td>645.9</td>
<td>N/A</td>
<td>2,072.5</td>
</tr>
<tr>
<td>Unallocated</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>75.3</td>
<td>293.3</td>
<td>423.9</td>
<td>N/A</td>
<td>792.4</td>
</tr>
</tbody>
</table>

Data from the AMRAB MRFF Priorities Consultation, Melbourne, 30th July 2018

Estimated $792.4 million of unallocated funds... **OPPORTUNITY FOR PRIORITY INFLUENCE**
## MRFF STRATEGY & CURRENT PRIORITIES

<table>
<thead>
<tr>
<th>Strategic Platforms</th>
<th>2016-2018 Priorities (OLD)</th>
<th>2018-2020 Priorities (NEW)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Strategic and international horizons</strong></td>
<td>Antimicrobial resistance</td>
<td>One Health – Antimicrobial Resistance</td>
</tr>
<tr>
<td></td>
<td>International collaborative research</td>
<td>Global Health and Health Security</td>
</tr>
<tr>
<td></td>
<td>Disruptive technology</td>
<td>Aboriginal and Torres Strait Islander Health</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ageing and Aged Care</td>
</tr>
<tr>
<td><strong>Data and infrastructure</strong></td>
<td>Clinical quality registries</td>
<td>Digital Health Intelligence</td>
</tr>
<tr>
<td></td>
<td>National data management study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MRFF infrastructure and evaluation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Communicable disease control</td>
<td></td>
</tr>
<tr>
<td><strong>Health services and systems</strong></td>
<td>National Institute of Research</td>
<td>Comparative Effectiveness Research</td>
</tr>
<tr>
<td></td>
<td>Building evidence in primary care</td>
<td>Primary Care Research</td>
</tr>
<tr>
<td></td>
<td>Behavioural economics application</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug effectiveness and repurposing</td>
<td></td>
</tr>
<tr>
<td><strong>Capacity and collaboration</strong></td>
<td>National infrastructure sharing scheme</td>
<td>Clinical Researcher Capacity</td>
</tr>
<tr>
<td></td>
<td>Industry exchange fellowships</td>
<td>Consumer-Driven Research</td>
</tr>
<tr>
<td></td>
<td>Clinical researcher fellowships</td>
<td>Drug Repurposing</td>
</tr>
<tr>
<td><strong>Trials and translation</strong></td>
<td>Clinical trial network</td>
<td>Public Health Interventions</td>
</tr>
<tr>
<td></td>
<td>Public good demonstration trials</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Targeted translation topics</td>
<td></td>
</tr>
<tr>
<td><strong>Commercialisation</strong></td>
<td>Research incubator hubs</td>
<td>Translational Research Infrastructure</td>
</tr>
<tr>
<td></td>
<td>Biomedical translation</td>
<td></td>
</tr>
<tr>
<td>Theme</td>
<td>Scheme</td>
<td>$m</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>National Missions</td>
<td>Australian Brain Cancer Mission (*50/50 MRFF/industry)</td>
<td>100*</td>
</tr>
<tr>
<td></td>
<td>Million Minds Mental Health Mission</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td>Genomic Health Futures Mission</td>
<td>500</td>
</tr>
<tr>
<td>Clinical Trials Programs</td>
<td>Rare cancers, rare diseases, unmet need clinical trials &amp; registries program</td>
<td>206</td>
</tr>
<tr>
<td></td>
<td>International clinical trial collaborations</td>
<td>42</td>
</tr>
<tr>
<td>Public Health and Health Services</td>
<td>Keeping Australians Out of Hospital program</td>
<td>18.1</td>
</tr>
<tr>
<td></td>
<td>Targeted Health System and Community Organisation Research program</td>
<td>39.8</td>
</tr>
<tr>
<td></td>
<td>Women’s Health and research into Maternal Health and First 2,000 Days</td>
<td>17.5</td>
</tr>
<tr>
<td>Targeted Translation Research Accelerator</td>
<td>Chronic conditions focussed on diabetes and heart disease</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td>Endometriosis</td>
<td>2.5</td>
</tr>
<tr>
<td>Rapid Applied Research Translation</td>
<td>Advanced Health Research Translation Centres ($6.0-6.1m each)</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td>Centres for Innovation in Regional Health</td>
<td></td>
</tr>
<tr>
<td>Frontier Health</td>
<td>Frontier Health and Medical Research Program</td>
<td>240</td>
</tr>
<tr>
<td>Industry Collaboration</td>
<td>Industry-research collaboration</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Biomedical and medical technology programs</td>
<td>62.3</td>
</tr>
<tr>
<td>Next generation clinical researchers</td>
<td>Clinical researcher fellowships (NHMRC) (CDF, TRIP, PF)</td>
<td>70</td>
</tr>
</tbody>
</table>
## MONASH MRFF Contestable Calls Currently Open

<table>
<thead>
<tr>
<th>Theme</th>
<th>Title</th>
<th>Acronym</th>
<th>Opened</th>
<th>Close</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials</td>
<td>International Clinical Trial Collaborations Program</td>
<td>ICTC-2</td>
<td>06.12.18</td>
<td>10.04.19</td>
<td>OPEN</td>
</tr>
<tr>
<td>Million Minds Missions</td>
<td>Million Minds Missions – Round 1</td>
<td>MM2018</td>
<td>12.12.18</td>
<td>20.02.19</td>
<td>OPEN</td>
</tr>
<tr>
<td>Frontier Health</td>
<td>Frontier Health and Medical Research</td>
<td></td>
<td>12.12.18</td>
<td>26.02.19</td>
<td>OPEN</td>
</tr>
<tr>
<td>Industry Collaboration</td>
<td>Researcher Exchange and Development within Industry (REDI)</td>
<td>REDI</td>
<td>12.02.19</td>
<td>09.04.19</td>
<td>OPEN</td>
</tr>
</tbody>
</table>

*CALL FOR HOST ORGANISATIONS ONLY*
<table>
<thead>
<tr>
<th>Theme</th>
<th>Title</th>
<th>Acronym</th>
<th>Opened</th>
<th>Closed</th>
<th>Status</th>
<th>Monash Awards</th>
<th>Monash Total</th>
<th>% of Call Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMR</td>
<td>Antimicrobial Resistance - Targeted Call for Research</td>
<td>AMR-TCR</td>
<td>24.08.17</td>
<td>04.10.17</td>
<td>AWARDED</td>
<td>1</td>
<td>$1,826,398</td>
<td>30.96</td>
</tr>
<tr>
<td>Clinical Trials</td>
<td>Rare Cancers, Rare Diseases and Unmet Need (Formerly - Lifting Clinical Trials …)</td>
<td>RCRDUN 2017</td>
<td>24.08.17</td>
<td>04.10.17</td>
<td>AWARDED</td>
<td>5</td>
<td>$5,896,836</td>
<td>22.17</td>
</tr>
<tr>
<td>Clinical Trials</td>
<td>Low Survival Cancers and Diseases</td>
<td>LSCD</td>
<td>07.03.18</td>
<td>18.04.18</td>
<td>AWARDED</td>
<td>3</td>
<td>$4,501,015</td>
<td>47.46</td>
</tr>
<tr>
<td>Clinical Trials</td>
<td>Rare Cancers, Rare Diseases and Unmet Need</td>
<td>RCRDUN 2018</td>
<td>25.06.18</td>
<td>16.08.18</td>
<td>AWARDED</td>
<td>6</td>
<td>$8,550,576</td>
<td>21.31</td>
</tr>
<tr>
<td>Clinical Trials</td>
<td><em>Return to life, return to work</em> clinical research grants for 2019</td>
<td>PSE/RTW 2018</td>
<td>08.10.18</td>
<td>30.11.18</td>
<td>CLOSED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials</td>
<td>International Clinical Trial Collaborations Program</td>
<td>ICTC -1</td>
<td>10.10.18</td>
<td>21.11.18</td>
<td>CLOSED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accelerated Research</td>
<td>Movember - Prostate Cancer research Alliance</td>
<td>PCRA 2018</td>
<td>31.10.18</td>
<td>19.12.18</td>
<td>CLOSED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accelerated Research</td>
<td>Stem Cells Australia - Targeted Disease Teams</td>
<td>SCA 2018</td>
<td>13.11.18</td>
<td>15.02.19</td>
<td>CLOSED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public Health</td>
<td>Keeping Australian’s Out of Hospital</td>
<td>KAOH</td>
<td>28.11.18</td>
<td>30.01.19</td>
<td>CLOSED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public Health</td>
<td>Targeted Health System and Community Organisation Research program</td>
<td>THSR 2018</td>
<td>12.12.2018</td>
<td>06.02.19</td>
<td>CLOSED</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MRFF MISSION
AUSTRALIAN BRAIN CANCER MISSION
$100m ($50m from MRFF, 10 years from 2017-18)

- funding partners are making significant contributions to the funding goal of $100 million:
  - Cure Brain Cancer Foundation, Minderoo Foundation's Eliminate Cancer Initiative, Carrie's Beanies 4 Brain Cancer and the Mark Hughes Foundation.

- Managed by Cancer Australia. One small clinical trial call already via NHMRC.
• new and expanded clinical flagship studies (rare diseases, rare cancers and complex conditions);
• new clinical trials and technology applications;
• increased academic and researcher collaboration and new career pathways;
• co-investment with philanthropy and business to support new industries;
• community dialogue to understand the value of genomics (privacy, legal, social and familial impact);
• analytical power backed by national standards and protocols (secure data, access, analysis, data sharing)
• call expected early 2019
• Research into the causes, prevention and treatment of mental illness
• Support innovative, systems-based research that addresses key national health priorities (outlined in the Fifth National Mental Health and Suicide Prevention Plan)
• Priorities:
  • Aboriginal and Torres Strait Islander mental health, child and youth mental health, eating disorders (CALL OPEN) suicide prevention, depression, anxiety, bipolar disorder, other areas of critical importance to national mental health and wellbeing
Increase access to national and international clinical trials and accelerate research in areas of identified unmet need.

- $206m over 5 years to extend Rare Cancers, Rare Diseases and Unmet Need Clinical Trials program
- $42m over 5 years new funding to support international clinical trial collaborations
- 2 calls already
- 15 Feb Monash/Monash Partners awarded 6 grants, $8,550,576 (21% of national pool)
• Funding for innovative ‘out of the box’ ideas and discoveries and groundbreaking research which promises new treatments and technologies to improve health, and open new markets for industry growth.

• Overseen by a panel of experts, Australia and International (TBA)

• Call opened Dec 6th, closes Feb 26th
FRONTIER HEALTH AND MEDICAL RESEARCH PROGRAM

• Two stage process:

  • Stage one: $250k - $1M for 1 year (up to $10M total awarded)
    • competitive expression of interest, where researchers articulate their idea and its merit, and demonstrate its novelty, competitiveness and transformative nature, and its potential for partnerships. Successful applicants will have approximately one year to advance their idea, ready to put forward for potential stage two investment.

  • Stage two: $10-20m per year for up to 5 years (up to $230M total awarded)
    • support the best applicants to realise a new frontier in health and medical research and build new industry ecosystems.
TARGETED TRANSLATION RESEARCH ACCELERATOR
DIABETES AND HEART DISEASE
$125m (9 years from 2019-20)

- Support for early stage health and medical research discoveries to reach proof-of-concept and progress to human clinical trials.
- Philanthropic and business funding expected to co-invest with Government.
- Overseen by an international panel of experts (TBA) who will identify specific priority areas and co-funding models.
- 4th Feb Greg Hunt announced $25 in a contestable grant round COMING SOON
TRANSLATION
PUBLIC HEALTH AND HEALTH SERVICES
$75.4m (4 years from 2017-18)

- Keeping Australians Out of Hospital program ($18.1m) Closed 30 Jan
- Targeted Health System and Community Organisation Research program ($39.8m) Closed 06 Feb
- Women’s Health and research into Maternal Health and First 2,000 Days ($17.5m)
- PLUS: Advanced Health Research Translation Centres (AHRTCs $6.0-6.1m each) (75m); Centres for Innovation in Regional Health. Monash Partners is our AHRTC.
THE BIOMEDICAL TRANSLATION BRIDGE

The Biomedical Translation Bridge grant opportunity will support one or more organisations to fund and nurture early stage health and medical research ventures to reach proof-of-concept stage with potential to attract further capital and support.

It will provide $22.3 million over four years from 2018 to 2022 as follows.

- $10.4 million in 2018-19
- $5.3 million in 2019-20
- $5.3 million in 2020-21
- $1.3 million in 2021-22.

Applications to offer this program closed on 21 August 2018 and are under consideration.

Details are available at https://www.business.gov.au/Assistance/Biomedical-Translation-Bridge
WHAT’S NEXT???

Congenital Heart Disease
$20M for Research. The funding is for an open grant round aimed at better understanding the disease’s genetic causes and prevention and treatment options. NOTE: This is not yet a call for applications, only an announcement of the intention to run a grant round.

Dementia, Ageing and Aged Care Mission.
$185 million over 10-year
Dementia (diagnosis, treatment and prevention)
• Fall prevention and avoidable hospitalisations
• Assistive technology to support independence
<table>
<thead>
<tr>
<th>Role</th>
<th>Department / Team</th>
<th>Contacts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Karen McConalogue</td>
<td>Director, MRFF Initiatives</td>
<td>Central point of contact</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stakeholder management (internal and external) and communication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Management of administration support resources/personnel</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Amalgamation of intelligence about funding announcements, external consortia, internal bid development</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Expression of Interest form and Information Register</td>
</tr>
<tr>
<td>Proposal Writing</td>
<td>MNHS External Engagement Team</td>
<td>Dr Megan Astle</td>
</tr>
<tr>
<td>Administration</td>
<td>MNHS Research Office</td>
<td>Dr Svetozar Kovacevic, Dr Bev Cottle</td>
</tr>
<tr>
<td>Tactical Advice</td>
<td>MRO – Research Development&lt;br&gt; MNHS Research Office&lt;br&gt;MNHS External Engagement</td>
<td>Dr Gabrielle Callander, Luke McAvaney&lt;br&gt;Svetozar Kovacevic, Bev Cottle&lt;br&gt;Megan Astle</td>
</tr>
<tr>
<td>Communications</td>
<td>MNHS Research Office&lt;br&gt; MRO – Medical and Health Sciences</td>
<td>Svetozar Kovacevic, Bev Cottle&lt;br&gt;Dr Tsharni Zazryn</td>
</tr>
</tbody>
</table>
Monash has secured significantly more contestable MRFF funding in 2018 vs 2017.

<table>
<thead>
<tr>
<th>University</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monash University</td>
<td>3,247,608</td>
<td>13,172,363</td>
</tr>
<tr>
<td>The University of Sydney</td>
<td>1,821,109</td>
<td>7,221,885</td>
</tr>
<tr>
<td>The University of Queensland</td>
<td>577,189</td>
<td>5,932,995</td>
</tr>
<tr>
<td>The University of Melbourne</td>
<td>2,537,458</td>
<td>4,262,006</td>
</tr>
<tr>
<td>The University of Western Australia</td>
<td>1,170,756</td>
<td>4,716,445</td>
</tr>
<tr>
<td>The University of New South Wales</td>
<td>2,022,271</td>
<td>2,380,850</td>
</tr>
<tr>
<td>The University of Adelaide</td>
<td>431,000</td>
<td>1,191,769</td>
</tr>
<tr>
<td>The Australian National University</td>
<td>179,118</td>
<td>887,072</td>
</tr>
<tr>
<td>Non-Go8</td>
<td>5,130,269</td>
<td>9,629,158</td>
</tr>
<tr>
<td>Total</td>
<td>17,116,777</td>
<td>49,394,543</td>
</tr>
</tbody>
</table>

*Includes 1 TRIP 2019 fellowship ($181,066) which is not represented in the adjacent table.

Monash Partners were awarded grants totalling $2.22M in 2018 and $1.97M in 2019 (first part of the $6.1M awarded to the Partners).

*by award date
Connecting researchers, clinicians and the community to innovate for better health

Professor Helena Teede
Executive Director

Dr Angela Jones
Chief Operating Officer
Value add and strategic benefit of Monash Partners

- Strategic support
- Networking
- Engagement
- Reach
- National linkage & coordination
- In kind support
- Seed funding
- Health service embedding
- Integrated with Monash University team
Thank you

www.monashpartners.org.au